References
- Barst RJ, Ivy D, Dingemanse J, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2003;73:372–82
- Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005;46: 697–704
- Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92:664–670
- Widlitz A, Barst RJ. Pulmonary arterial hypertension in children. Eur Respir J 2003; 21:155–76
- Fraisse A, Godart F Bonnet D, et al. The French registry of pulmonary arterial hypertension in children: rationale and design. Curr Med Res Opin 2007;23\(Suppl. 2):27–33
- D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343–9
- Sandoval J, Bauerle O, Gomez A, et al. Primary pulmonary hypertension in children: clinical characterization and survival. J Am Coll Cardiol 1995;25:466–74
- Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43: 5–12S
- Palmer SM, Robinson LJ, Wang A, et al. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease. Chest 1998;113:237–40
- McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first line-bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005;25:244–49
- Galiè N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J 2004;25:2243–78
- Galiè N, Seeger N, Naeije R, Simonneau G, et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004 43:81–8S
- Yung D, Wildlitz A, Rosenzweig E, et al. Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation 2004;110(6):660–5
- Rubin L, Badesch D, Barst R, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346: 896–903
- Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003;124:247–54
- Galiè N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004;61: 227–37